Market News AIOpen the app

TARS stock news · Tarsus Pharmaceuticals

Stories about Tarsus Pharmaceuticals (TARS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for TARS

Follow Tarsus Pharmaceuticals (TARS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TARS
Free on the App Store and Google Play, or on the web.
  1. Nov 3, 2026, 5:49 PM ET · Results

    Tarsus Pharmaceuticals shared its Q3 2026 earnings, showing record sales of $194.6 million and raising its yearly sales forecast.

    Good for TARS

    Tarsus reported Q3 sales of $194.6 million and raised its 2026 XDEMVY sales forecast to $715 million–$730 million. Strong demand makes this positive for the company.